Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Change in Accured Expenses for 9 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 547.82% to $12.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $465000.0, a 85.68% decrease, with the full-year FY2025 number at $465000.0, down 85.68% from a year prior.
  • Change in Accured Expenses was $12.7 million for Q4 2025 at Denali Therapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $24.6 million in Q3 2024 to a low of -$32.2 million in Q2 2023.
  • A 5-year average of $1.1 million and a median of $2.1 million in 2024 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: tumbled 649.17% in 2023, then soared 3249.59% in 2024.
  • Denali Therapeutics' Change in Accured Expenses stood at $7.8 million in 2021, then crashed by 48.16% to $4.0 million in 2022, then skyrocketed by 255.43% to $14.3 million in 2023, then crashed by 119.86% to -$2.8 million in 2024, then surged by 547.82% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Change in Accured Expenses are $12.7 million (Q4 2025), $1.9 million (Q3 2025), and -$7.7 million (Q2 2025).